抗艾滋病药物 90. 新型 C-28 修饰的比韦马胺类似物作为有效的 HIV 成熟抑制剂。
Anti-AIDS agents 90. novel C-28 modified bevirimat analogues as potent HIV maturation inhibitors.
机构信息
Natural Products Research Laboratories, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, USA.
出版信息
J Med Chem. 2012 Sep 27;55(18):8128-36. doi: 10.1021/jm301040s. Epub 2012 Sep 14.
Abstract
In a continuing study of bevirimat (2), the anti-HIV-maturation clinical trials agent, 28 new betulinic acid (BA, 1) derivatives were designed and synthesized. Among these compounds, 17, with a C-28 MEM ester moiety, and 22, with a C-28 ethyl hexanoate, increased the anti-HIV replication activity compared with 2 by 2-fold while compounds 40, 41, 48, and 49, with C-28 piperazine or piperidine amide substitutions, increased the activity by 3- to 15-fold. The best new compound, 41, exhibited an anti-HIV IC(50) of 0.0059 μM compared with 0.087 μM for 2. All of the active compounds showed only antimaturation effects, as confirmed by TZM-bl assay, in blocking the HIV replication. The results suggest that proper C-28 substitutions can further enhance the antimaturation activity of 2 without any antientry effects. Thus, 41 may serve as a promising new lead for development of anti-AIDS clinical trial candidates.
摘要
在对艾滋病毒成熟抑制剂 bevirimat（2）的持续研究中，设计并合成了 28 种新型桦木酸（BA，1）衍生物。这些化合物中，17 位带有 C-28 MEM 酯基，22 位带有 C-28 乙酯，与 2 相比，抗 HIV 复制活性提高了 2 倍，而 40、41、48 和 49 位带有 C-28 哌嗪或哌啶酰胺取代基，活性提高了 3 到 15 倍。最好的新化合物 41 的抗 HIV IC（50）为 0.0059 μM，而 2 的抗 HIV IC（50）为 0.087 μM。所有具有活性的化合物都仅显示出成熟阻断作用，这通过 TZM-bl 试验得到证实，可阻断 HIV 复制。结果表明，适当的 C-28 取代可以进一步提高 2 的成熟阻断活性，而不会产生任何进入抑制作用。因此，41 可能成为开发抗艾滋病临床试验候选药物的有前途的新先导化合物。
相似文献
1
Anti-AIDS agents 90. novel C-28 modified bevirimat analogues as potent HIV maturation inhibitors.抗艾滋病药物 90. 新型 C-28 修饰的比韦马胺类似物作为有效的 HIV 成熟抑制剂。
J Med Chem. 2012 Sep 27;55(18):8128-36. doi: 10.1021/jm301040s. Epub 2012 Sep 14.
2
Alkyl Amine Bevirimat Derivatives Are Potent and Broadly Active HIV-1 Maturation Inhibitors.烷基胺贝维拉马衍生物是强效且具有广泛活性的HIV-1成熟抑制剂。
Antimicrob Agents Chemother. 2015 Oct 19;60(1):190-7. doi: 10.1128/AAC.02121-15. Print 2016 Jan.
3
Incorporation of Privileged Structures into Bevirimat Can Improve Activity against Wild-Type and Bevirimat-Resistant HIV-1.将优势结构引入比维莫德可提高其对野生型和比维莫德耐药的HIV-1的活性。
J Med Chem. 2016 Oct 13;59(19):9262-9268. doi: 10.1021/acs.jmedchem.6b00461. Epub 2016 Sep 22.
4
Anti-AIDS agents 81. Design, synthesis, and structure-activity relationship study of betulinic acid and moronic acid derivatives as potent HIV maturation inhibitors.抗艾滋病药物 81. 桦木酸和莫诺苯宗衍生物作为有效的 HIV 成熟抑制剂的设计、合成及构效关系研究。
J Med Chem. 2010 Apr 22;53(8):3133-41. doi: 10.1021/jm901782m.
5
Anti-AIDS agents 73: structure-activity relationship study and asymmetric synthesis of 3-O-monomethylsuccinyl-betulinic acid derivatives.抗艾滋病药物73：3 - O - 单甲基琥珀酰桦木酸衍生物的构效关系研究及不对称合成
Bioorg Med Chem Lett. 2007 Dec 1;17(23):6553-7. doi: 10.1016/j.bmcl.2007.09.081.
6
Synthesis of betulinic acid derivatives as entry inhibitors against HIV-1 and bevirimat-resistant HIV-1 variants.桦木酸衍生物的合成作为抗 HIV-1 和抗 bevirimat 的 HIV-1 变异体的进入抑制剂。
Bioorg Med Chem Lett. 2012 Aug 15;22(16):5190-4. doi: 10.1016/j.bmcl.2012.06.080. Epub 2012 Jul 3.
7
Synthesis and biological evaluation of a new derivative of bevirimat that targets the Gag CA-SP1 cleavage site.合成和生物评价一种新的靶向 Gag CA-SP1 切割位点的贝韦利姆的衍生物。
Eur J Med Chem. 2013 Apr;62:453-65. doi: 10.1016/j.ejmech.2013.01.013. Epub 2013 Jan 19.
8
Discovery and synthesis of novel beesioside I derivatives with potent anti-HIV activity.发现并合成具有强效抗 HIV 活性的新型贝西醇 I 衍生物。
Eur J Med Chem. 2019 Mar 15;166:159-166. doi: 10.1016/j.ejmech.2019.01.020. Epub 2019 Jan 10.
9
Fluorinated betulinic acid derivatives and evaluation of their anti-HIV activity.氟化桦木酸衍生物及其抗HIV活性评估。
Bioorg Med Chem Lett. 2016 Jan 1;26(1):68-71. doi: 10.1016/j.bmcl.2015.11.029. Epub 2015 Nov 11.
10
Bifunctional anti-human immunodeficiency virus type 1 small molecules with two novel mechanisms of action.具有两种新型作用机制的双功能抗1型人类免疫缺陷病毒小分子
Antimicrob Agents Chemother. 2004 Feb;48(2):663-5. doi: 10.1128/AAC.48.2.663-665.2004.
引用本文的文献
1
The utility of integrating nanopore sequencing into routine HIV-1 drug resistance surveillance.将纳米孔测序整合到常规HIV-1耐药性监测中的实用性。
Microb Genom. 2025 Mar;11(3). doi: 10.1099/mgen.0.001375.
2
C-28 linker length modulates the activity of second-generation HIV-1 maturation inhibitors.C-28连接子长度调节第二代HIV-1成熟抑制剂的活性。
Virol J. 2025 Jan 29;22(1):20. doi: 10.1186/s12985-025-02635-8.
3
Betulinic Acid Decorated with Polar Groups and Blue Emitting BODIPY Dye: Synthesis, Cytotoxicity, Cell-Cycle Analysis and Anti-HIV Profiling.带有极性基团和蓝色发光BODIPY染料的桦木酸：合成、细胞毒性、细胞周期分析及抗HIV分析
Biomedicines. 2021 Aug 28;9(9):1104. doi: 10.3390/biomedicines9091104.
4
A single G10T polymorphism in HIV-1 subtype C Gag-SP1 regulates sensitivity to maturation inhibitors.HIV-1 亚型 C Gag-SP1 中的单个 G10T 多态性调节对成熟抑制剂的敏感性。
Retrovirology. 2021 Apr 9;18(1):9. doi: 10.1186/s12977-021-00553-5.
5
Design, synthesis, and structure activity relationship analysis of new betulinic acid derivatives as potent HIV inhibitors.新型白桦脂酸衍生物的设计、合成及构效关系分析作为有效的 HIV 抑制剂。
Eur J Med Chem. 2021 Apr 5;215:113287. doi: 10.1016/j.ejmech.2021.113287. Epub 2021 Feb 14.
6
HIV-1 Maturation: Lessons Learned from Inhibitors.HIV-1 成熟：抑制剂带来的启示。
Viruses. 2020 Aug 26;12(9):940. doi: 10.3390/v12090940.
7
Recent advances in natural anti-HIV triterpenoids and analogs.天然抗 HIV 三萜及其类似物的最新进展。
Med Res Rev. 2020 Nov;40(6):2339-2385. doi: 10.1002/med.21708. Epub 2020 Jul 14.
8
Recent Advances in HIV-1 Gag Inhibitor Design and Development.HIV-1 衣壳抑制剂设计与开发的最新进展
Molecules. 2020 Apr 7;25(7):1687. doi: 10.3390/molecules25071687.
9
Recent Achievements in Medicinal and Supramolecular Chemistry of Betulinic Acid and Its Derivatives .桦木酸及其衍生物的药用和超分子化学的最新研究进展。
Molecules. 2019 Sep 30;24(19):3546. doi: 10.3390/molecules24193546.
10
Synthesis and Structure-Activity Relationship Correlations of Gnidimacrin Derivatives as Potent HIV-1 Inhibitors and HIV Latency Reversing Agents.Gnidimacrin 衍生物的合成及构效关系研究作为有效的 HIV-1 抑制剂和 HIV 潜伏逆转剂。
J Med Chem. 2019 Aug 8;62(15):6958-6971. doi: 10.1021/acs.jmedchem.9b00339. Epub 2019 Jul 25.
本文引用的文献
1
Anti-AIDS agents 81. Design, synthesis, and structure-activity relationship study of betulinic acid and moronic acid derivatives as potent HIV maturation inhibitors.抗艾滋病药物 81. 桦木酸和莫诺苯宗衍生物作为有效的 HIV 成熟抑制剂的设计、合成及构效关系研究。
J Med Chem. 2010 Apr 22;53(8):3133-41. doi: 10.1021/jm901782m.
2
Anti-AIDS agents. 78. Design, synthesis, metabolic stability assessment, and antiviral evaluation of novel betulinic acid derivatives as potent anti-human immunodeficiency virus (HIV) agents.抗艾滋病药物。78. 新型桦木酸衍生物作为强效抗人类免疫缺陷病毒（HIV）药物的设计、合成、代谢稳定性评估及抗病毒评价。
J Med Chem. 2009 May 28;52(10):3248-58. doi: 10.1021/jm900136j.
3
HIV entry inhibitors and their potential in HIV therapy.HIV进入抑制剂及其在HIV治疗中的潜力。
Med Res Rev. 2009 Mar;29(2):369-93. doi: 10.1002/med.20138.
4
The Design and Synthesis of Highly Branched and Spherically Symmetric Fluorinated Oils and Amphiles.高度支化且球对称的氟化油和两亲分子的设计与合成
Tetrahedron. 2007 May 7;63(19):3982-3988. doi: 10.1016/j.tet.2007.03.004.
5
Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection.单剂量3 - O -（3'，3'-二甲基琥珀酰基）桦木酸（贝维拉马特）抗人免疫缺陷病毒感染的安全性、病毒学效应及药代动力学/药效学的I期和II期研究
Antimicrob Agents Chemother. 2007 Oct;51(10):3574-81. doi: 10.1128/AAC.00152-07. Epub 2007 Jul 16.
6
Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers.新型HIV成熟抑制剂贝维拉马在健康志愿者中的多剂量药代动力学及安全性研究
Clin Pharmacokinet. 2007;46(7):589-98. doi: 10.2165/00003088-200746070-00004.
7
Safety and pharmacokinetics of Bevirimat (PA-457), a novel inhibitor of human immunodeficiency virus maturation, in healthy volunteers.新型人类免疫缺陷病毒成熟抑制剂贝维拉马（PA - 457）在健康志愿者中的安全性和药代动力学
Antimicrob Agents Chemother. 2007 Sep;51(9):3063-6. doi: 10.1128/AAC.01391-06. Epub 2007 Jun 18.
8
Synthesis and anti-HIV activity of bi-functional betulinic acid derivatives.双功能桦木酸衍生物的合成及其抗HIV活性
Bioorg Med Chem. 2006 Apr 1;14(7):2279-89. doi: 10.1016/j.bmc.2005.11.016. Epub 2005 Nov 28.
9
F-18 Polyethyleneglycol stilbenes as PET imaging agents targeting Abeta aggregates in the brain.作为正电子发射断层显像（PET）成像剂的F-18聚乙二醇芪类化合物，用于靶向大脑中的β-淀粉样蛋白聚集体。
Nucl Med Biol. 2005 Nov;32(8):799-809. doi: 10.1016/j.nucmedbio.2005.06.001.
10
Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome.高效抗逆转录病毒疗法：当前技术水平、新型药物及其对改善治疗效果有用的药物相互作用。
Curr Pharm Des. 2005;11(14):1805-43. doi: 10.2174/1381612053764869.
Zotero 插件